Academy of Pharmaceutical Sciences
'Promoting the pharmaceutical sciences'


Shire gears up to battle Allergan's Linzess with new constipation drug Motegrity.....           Pfizer again supplying pain drugs to veterinarians shunted aside because of hospital shortages.....           As promised, Novartis eyes new method for funding ultrapricey next-gen drugs: FT.....           What to do when an exposť tanks your stock? For J&J, you go direct to consumers.....           Bristol-Myers Squibb nears $1.6B sale of OTC unit Upsa to Taisho: report.....           AbbVie streamlines management team to 4 executives under CEO Gonzalez.....           Boehringer employees go door-to-door delivering holiday hope to lung cancer patients.....           FiercePharmaAsia?Possible Sun probe; Huahai warning letter; Eisai-UCL neuro pact.....           FDA lets generics makers keep their legal shield, handing embattled industry a win.....           Teva to move global HQ to Tel Aviv amid $3B cost-cutting drive.....           J&J stock tumbles after Reuters reports it hid asbestos in talc.....           Neurocrine's 3rd Ingrezza flop in Tourette dashes hopes for sales expansion.....           Orchard Therapeutics commits to gene therapies production facility with plans to hire 100 workers.....           Mylan, Biocon copy inches closer to challenging Sanofi's long-suffering Lantus.....           Whistleblower complaint against Sun Pharma confirmed by Indian regulators: report.....           Warning, investors: Way too many drugs will be vying for market share in 15 diseases.....           Merck looks past Sanofi's dengue woes in development deal with Brazilian vaccine institute.....           Can Bristol-Myers' latest Opdivo results preserve its small-cell lung cancer nod?.....           AstraZeneca mines for positives in Imfinzi's failed Mystic lung cancer trial.....           C4XD, Horizon to develop synthetic lethality targets in oncology.....           Fuji Pharma acquires minority stake in Alvotech.....           Vedanta begins phase 2 trial of LBP candidate VE303 for rCDI.....           Teva reports positive results for fremanezumab in phase IIIb migraine trial.....           'Bad drug' lawsuit ads hurt doc-patient relationships and need regulation, says industry coalition.....           AstraZeneca kicks off second blood cancer launch, this time for orphan drug Lumoxiti.....           Senator to Pfizer CEO: Stop playing 'political games' with drug prices.....           Pfizer still unable to get on top of problems at Hospira injectables plant.....           U.K. cost watchdog NICE issues preliminary ?no? on Alnylam?s Onpattro and Ionis? Tegsedi.....           Johnson & Johnson?s Tremfya tops Novartis blockbuster Cosentyx in head-to-head psoriasis showdown.....           Merck promotes oncology, vaccine executives to replace Adam Schechter in commercial rejig.....           FDA Commissioner Scott Gottlieb blasts insulin pricing, unveils move to bolster biosimilar competition.....           As competition heats up, U.S. prices for Remicade and biosims slip: analyst.....           China's Zhejiang Huahai lambasted in FDA warning letter for putting profits ahead of safety.....           China's Zhejiang Huahai lambasted in FDA warning letter for putting profits ahead of safety.....           Boehringer Ingelheim chops 295 jobs in France but vows $380M in animal health investments.....           Boehringer Ingelheim chops 295 jobs in France but vows $380M in animal health investments.....           Merck promotes oncology, vaccine executives to replace Adam Schechter in commercial rejig.....           Merck promotes oncology, vaccine executives to replace Adam Schechter in commercial rejig.....           Lilly, AC Immune to collaborate on Alzheimer?s drug development.....           Novartis gets EC approval for self-administration of Xolair across all indications.....           Teva, Celltrion get FDA nod for Roche?s breast cancer drug biosimilar.....           Innovent, Incyte sign collaboration deal for three clinical-stage product candidates.....           European CHMP adopts positive opinion for Pfizer?s oncology biosimilar Zirabev.....           GlaxoSmithKline's Shingrix shortage expected to persist 'throughout 2019'.....           GlaxoSmithKline's Shingrix shortage expected to persist 'throughout 2019'.....           Cannes Lions Health preps for 6th year, names jury heads for health & wellness, pharma awards.....           Gilead, looking for cancer sales, swipes Roche pharma chief Daniel O'Day for CEO post.....           Akorn's CEO bows out after failing last-ditch bid to save Fresenius merger.....           Generics 'cartel' probe expands to a whopping 300 drugs: report.....           Gilead, looking for cancer sales, swipes Roche pharma chief O'Day for CEO post.....           RSS NEWSFEED....
Welcome to
The Academy of
Pharmaceutical Sciences
 
The Academy of Pharmaceutical Sciences (APS) is the UK-based professional membership body for Pharmaceutical Scientists.

We represent individuals and organisations from around the globe, throughout their development, in the delivery of excellence in the Pharmaceutical Science sector.
 
 
Latest news

Kingston University and Athlone Institute of Technology achieve APS accreditation

               

The Academy of Pharmaceutical Sciences (APS) is delighted to announce that two more institutions, Kingston University and Athlone Institute of Technology have recently achieved accreditation having gone through the accreditation process set up by the Academy towards the end of 2017.

APS is delighted that institutions see the value of our accreditation process and several others are in the process of application to us.

Achieving accreditation gives assurance to students and employers that the course meets the high standards required by the Academy and that these standards will be maintained throughout the 5-year period of accreditation.

APS believes that the accreditation process will raise the profile of pharmaceutical sciences in both academia and industry. The discipline is key in the discovery, development and manufacture of new medicines and as such is central to government initiatives to encourage the pharmaceutical industry to maintain and strengthen its strong base in the UK and Ireland.

The APS will continue to work with other stakeholders to build the science base for the ultimate benefit of patients.

To read more on the accreditation process - click here.

 
 
APS events overview

The APS is developing an exciting and informative programme of events in 2019.

Please take a look at our programme here.

OTHER EVENTS IN DEVELOPMENT
Developability for Biologicals
Inhaled Workshop
Basic Biopharmaceutics workshop 

Follow us
 
Upcoming Events
APS Additive Manufacturing Symposium
27 March 2019
APS Developability Workshop
17 - 18 April 2019
APS Industrial Insights 2019
25 - 26 April 2019
10th APS International PharmSci conference 2019
11 - 13 September 2019
Job Vacancies
View all Vacancies
Advertise your job vacancies
The APS is grateful for the support of:
Join Us

Join the academy and get discounts on events, post-nominals, latest news and more.

 

Academy of Pharmaceutical Sciences
Unit Q, Troon Way Business Centre
Humberstone Lane, Leicester, LE4 9HA
Tel: 0116 274 7351, Fax: 0116 274 7365, Email: info@apsgb.org

Terms of use:
The material included on this site is provided for information purposes only, and we make no representations or warranties as to its accuracy. Before relying on this material, you should take care to verify its accuracy, taking professional advice as appropriate.

Privacy Policy:
For details on the data we collect and how we store and process your data please refer to our Privacy Policy.